Vitruvian Partners completed the acquisition of a majority stake in DeepIntent for $637m.

Vitruvian Partners, an European private equity firm, completed the acquisition of a majority stake in DeepIntent, a demand-side platform that helps healthcare and pharma brands including AstraZeneca, Bayer, Gilead, and Johnson & Johnson buy ad space, for $637m. “This investment is a powerful vote of confidence—not only in DeepIntent, but in the essential role our industry plays at the intersection of healthcare and media. It affirms our mission to responsibly connect these worlds so that patients and doctors alike can access the knowledge they need to make informed decisions about life-changing treatments. We’ve never been more confident in our ability to harness data science and advertising to improve patient outcomes at scale.,” Chris Paquette, DeepIntent CEO and Founder.